Novel anthraquinone derivatives

Abstract

The invention relates to two novel substances, specifically (1R,2S,3S,4R)-3-acetoxy-1,2,4,5-tetrahydroxy-y-methoxy-2-methyl-1,2,3,4-tetrahydroanthracene-9,10-dione (3-O-acetyl-altersolanol M) (I) and 8-(4,5,6-trihydroxy-7-methyl-2-methoxy-9,10-dioxo-9H,10H-anthracene-1-yl)-(1S,2S,3R,4S)-1,2,3,4,5-pentahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-9H,10H-anthracene-9,10-dione (atropisomeric alterporriol I und J), (II) to the use thereof as anti-infective agents or anti-cancer agents, and to a production method therefor.

Description

technical field [0001] The present invention relates to a new anthraquinone derivative, its preparation method and its application method as an anti-infection drug, especially an anti-infection drug against multidrug-resistant pathogens, and an anticancer drug. Background technique [0002] In the late 1960s and early 1970s, due to the very successful use of antimicrobials, it was assumed that infectious diseases would no longer pose any risk. However, this proved to be a misconception, and, four decades later, microbes are posing a greater threat than ever. For these reasons, new antibacterial agents are urgently needed. Today, infectious diseases are the third most common cause of death in the United States and the second most common cause of death globally. Ineffective antimicrobial drugs are responsible for these conditions, and resistance of certain bacteria and fungi to these drugs poses a serious problem for our society. According to US statistics, most infections ...

AI Technical Summary

Problems solved by technology

In this case, the development of drug resistance is mainly due to the overexpression of integral membrane transporters such as P-glycoprotein, which leads to the efflux of the active substance from the cancer cell so that it is no longer effective

Images